Avapritinib

Product Description

Avapritinib is used to treat a certain type of stomach, bowel, or esophagus cancer called gastrointestinal stromal tumor (GIST) that cannot be treated with surgery or that has spread to other parts of the body (metastatic), and that is caused by a certain platelet-derived growth factor receptor alpha (PDGFRA) gene mutation. This medicine is also used to treat advanced systemic mastocytosis (AdvSM), including aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). Avapritinib belongs to the group of medicines known as antineoplastics. It interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal body cells may also be affected by sunitinib, other effects will also occur. Some of these may be serious and must be reported to your doctor. Other effects, like hair loss, may not be serious but may cause concern. Some effects may not occur for months or years after the medicine is used. (Sourced from: https://www.mayoclinic.org/drugs-supplements/avapritinib-oral-route/side-effects/drg-20484230?p=1)

Mechanisms of Action: KITl Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Belgium | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Italy | Latvia | Lithuania | Netherlands | Poland | Portugal | Romania | Slovakia | Spain | Sweden | Taiwan | United Kingdom | United States

Approved Indications: Oncology Unspecified

Known Adverse Events: Abdominal Pain | Dizziness | Pain Unspecified | Asthenia | Constipation | Diarrhea | Edema

Company: Royalty Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: Blueprint Medicines